Endpoints News 生物医药· ENDPOINTS·· 2026-10-20AI 评分49
辉瑞终止PF-06835375治疗特发性血小板减少性紫癜的II期临床试验
Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO
AI 导读
辉瑞(Pfizer)终止了针对罕见自身免疫疾病特发性血小板减少性紫癜(primary immune thrombocytopenia)的PF-06835375 II期临床试验。官方消息指出,该终止决定源于联邦临床监管机构(federal clinical …)的介入。文中未说明终止的具体临床原因(如安全性事件或疗效不足),也未提供已发布的完整研究数据。
正文
Pfizer halts Phase 2 autoimmune trial: The study was testing a program called PF-06835375 in the rare autoimmune disorder primary immune thrombocytopenia. The federal clinical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news